Rating Rationale
October 31, 2018 | Mumbai
Centenial Surgical Suture Limited
Ratings Reaffirmed
 
Rating Action
Total Bank Loan Facilities Rated Rs.20 Crore
Long Term Rating CRISIL BBB/Stable (Reaffirmed)
Short Term Rating CRISIL A3+ (Reaffirmed)
1 crore = 10 million
Refer to annexure for Details of Instruments & Bank Facilities
Detailed Rationale

CRISIL has reaffirmed its 'CRISIL BBB/Stable/CRISIL A3+' ratings on the bank facilities of Centenial Surgical Suture Limited (CCSL). The ratings continue to reflect a moderate business risk profile backed by an established position in the specialised coronary artery bypass graft (CABG) surgery segment and a strong relationship with customers and suppliers. The ratings also factor in a comfortable financial risk profile. These strengths are partially offset by a modest scale, and working capital-intensive nature, of operations, and exposure to competition and to volatility in raw material prices and foreign exchange (forex) rates.

Key Rating Drivers & Detailed Description
Strengths
* Healthy market position in the surgical suture industry: The company has been manufacturing surgical sutures for more than 20 years. It specialises in absorbable sutures used in CABG, where it has a 65% market share in India. The manufacturing capacity is 90% utilised and the facility is ISO 9001:2015 and Good Manufacturing Practices (GMP) certified. The company has a strong track record in terms of quality and availability. It has an exclusive technical and supply arrangement with Mani Corporation, Japan and has maintained relationships with reputed customers such as Narayana Hrudayalaya Hospitals, Wockhardt Hospitals, and Fortis Hospitals Ltd, among others for more than 10 years. The stable business risk profile is likely to be maintained, backed by the industry experience of the promoters.
 
* Comfortable financial risk profile: The networth was moderate at Rs 26.04 crore and the gearing low at 0.55 times, as on March 31, 2018. Debt protection metrics was above average, with interest coverage ratio at 3.0 times in fiscal 2018. The lack of any fixed repayment obligation enhances financial flexibility. The financial risk profile is likely to remain comfortable over the medium term on account of low debt and average profitability.
 
Weakness
* Modest scale, and working capital intensive nature, of operations: Operating income was modest at Rs 52.7 crore in fiscal 2018. Considering the size of the suture market, an increase in business scale would be limited and depend on the ability of to control a larger share in the CABG suture market and compete in other segments.
 
Gross current assets were over 300 days in the three fiscals ended March 31, 2018, driven by high debtors of over 4 months and inventory of more than 7 months. The high debtor days are because payments from medical institutions are linked to timely disbursals by medical insurance companies. Large inventory needs to be maintained to cater to the immediate demand from surgeons, as quality and timely availability of sutures are critical in maintaining relationships with customers.
 
* Susceptibility to volatility in raw material prices and forex rates:
The operating margin was 8.5-10.4% over the four fiscals through 2017-18. The company does not hedge its forex payables (against raw material imports), and hence profitability remains susceptible to volatility in raw material prices and forex rates. However, the margin has been maintained because of exclusive tie-ups with main suppliers and customers. Operating performance will remain susceptible to volatility in raw material prices and forex rates over the medium term.
Outlook: Stable

CRISIL believes CSSL will maintain its leadership position in the CABG segment over the medium term, supported by strong customer and vendor relationships and an experienced management. The outlook may be revised to 'Positive' in case of significant ramp-up in operations, while profitability and the capital structure are maintained. The outlook may be revised to 'Negative' if large, debt-funded capital expenditure, substantial increase in working capital requirement, or a sharp decline in revenue or profitability weakens the financial risk profile, particularly liquidity.

About the Company

Set up in 1995, CSSL is a publicly listed company that manufactures highly specialised absorbable and non-absorbable sutures (cardio vascular sutures and atraumatic needled sutures) that are primarily used in CABG surgeries. It sells products under Centisorb, Centicryl, Centisynth, Centicryl Rapid, Centisilk, Centilene, Centibond, Centlon, and Centsteel brands. CSSL received ISO 9001: 2008 certification for its manufacturing facility at Murbad in Thane, Maharashtra, and complies with the US Pharmacopeia Convention.

Key Financial Indicators
Particulars Unit 2018 2017
Revenue Rs crore 52.75 52.84
Profit after tax Rs crore 1.54 1.72
PAT margin % 2.92 3.3
Adjusted debt/adjusted networth Times 0.55 0.62
Interest coverage Times 3.0 2.79

Any other information: Not applicable

Note on complexity levels of the rated instrument:
CRISIL complexity levels are assigned to various types of financial instruments. The CRISIL complexity levels are available on www.crisil.com/complexity-levels. Users are advised to refer to the CRISIL complexity levels for instruments that they consider for investment. Users may also call the Customer Service Helpdesk with queries on specific instruments.
Annexure - Details of Instrument(s)
ISIN Name of instrument Date of
Allotment
Coupon
Rate (%)
Maturity date Issue
Size (Rs. Crore)
Rating Assigned
with Outlook
NA Bank guarantee NA NA NA 0.25 CRISIL A3+
NA Cash credit NA NA NA 15 CRISIL BBB/Stable
NA Letter of credit NA NA NA 4 CRISIL A3+
NA Proposed long term bank loan facility NA NA NA 0.75 CRISIL BBB/Stable
Annexure - Rating History for last 3 Years
  Current 2018 (History) 2017  2016  2015  Start of 2015
Instrument Type Outstanding Amount Rating Date Rating Date Rating Date Rating Date Rating Rating
Fund-based Bank Facilities  LT/ST  15.75  CRISIL BBB/Stable      31-10-17  CRISIL BBB/Stable  14-07-16  CRISIL BBB/Stable  30-06-15  CRISIL BBB/Stable  CRISIL BBB/Stable 
Non Fund-based Bank Facilities  LT/ST  4.25  CRISIL A3+      31-10-17  CRISIL A3+  14-07-16  CRISIL A3+  30-06-15  CRISIL A3+  CRISIL A3+ 
All amounts are in Rs.Cr.
Annexure - Details of various bank facilities
Current facilities Previous facilities
Facility Amount (Rs.Crore) Rating Facility Amount (Rs.Crore) Rating
Bank Guarantee .25 CRISIL A3+ Bank Guarantee 1 CRISIL A3+
Cash Credit 15 CRISIL BBB/Stable Cash Credit 13 CRISIL BBB/Stable
Letter of Credit 4 CRISIL A3+ Letter of Credit 4 CRISIL A3+
Proposed Long Term Bank Loan Facility .75 CRISIL BBB/Stable Proposed Long Term Bank Loan Facility 2 CRISIL BBB/Stable
Total 20 -- Total 20 --
Links to related criteria
CRISILs Approach to Financial Ratios
CRISILs Bank Loan Ratings - process, scale and default recognition
Rating criteria for manufaturing and service sector companies
CRISILs Bank Loan Ratings
The Rating Process
Understanding CRISILs Ratings and Rating Scales

For further information contact:
Media Relations
Analytical Contacts
Customer Service Helpdesk
Saman Khan
Media Relations
CRISIL Limited
D: +91 22 3342 3895
B: +91 22 3342 3000
saman.khan@crisil.com

Naireen Ahmed
Media Relations
CRISIL Limited
D: +91 22 3342 1818
B: +91 22 3342 3000
naireen.ahmed@crisil.com

Mohit Makhija
Director - CRISIL Ratings
CRISIL Limited
B:+91 124 672 2000
mohit.makhija@crisil.com


Aditya Munshi
Associate Director - CRISIL Ratings
CRISIL Limited
D:+91 22 4097 8105
aditya.munshi@crisil.com


Richa Gupta
Rating Analyst - CRISIL Ratings
CRISIL Limited
D:+91 22 3342 8551
Richa.Gupta@crisil.com
Timings: 10.00 am to 7.00 pm
Toll free Number:1800 267 1301

For a copy of Rationales / Rating Reports:
CRISILratingdesk@crisil.com
 
For Analytical queries:
ratingsinvestordesk@crisil.com


 

Note for Media:
This rating rationale is transmitted to you for the sole purpose of dissemination through your newspaper / magazine / agency. The rating rationale may be used by you in full or in part without changing the meaning or context thereof but with due credit to CRISIL. However, CRISIL alone has the sole right of distribution (whether directly or indirectly) of its rationales for consideration or otherwise through any media including websites, portals etc.


About CRISIL Limited

CRISIL is a leading agile and innovative, global analytics company driven by its mission of making markets function better. We are India’s foremost provider of ratings, data, research, analytics and solutions. A strong track record of growth, culture of innovation and global footprint sets us apart. We have delivered independent opinions, actionable insights, and efficient solutions to over 1,00,000 customers.
 
We are majority owned by S&P Global Inc., a leading provider of transparent and independent ratings, benchmarks, analytics and data to the capital and commodity markets worldwide.
 
For more information, visit www.crisil.com 


Connect with us: TWITTER | LINKEDIN | YOUTUBE | FACEBOOK

About CRISIL Ratings
CRISIL Ratings is part of CRISIL Limited (“CRISIL”). We pioneered the concept of credit rating in India in 1987. CRISIL is registered in India as a credit rating agency with the Securities and Exchange Board of India (“SEBI”). With a tradition of independence, analytical rigour and innovation, CRISIL sets the standards in the credit rating business. We rate the entire range of debt instruments, such as, bank loans, certificates of deposit, commercial paper, non-convertible / convertible / partially convertible bonds and debentures, perpetual bonds, bank hybrid capital instruments, asset-backed and mortgage-backed securities, partial guarantees and other structured debt instruments. We have rated over 24,500 large and mid-scale corporates and financial institutions. CRISIL has also instituted several innovations in India in the rating business, including rating municipal bonds, partially guaranteed instruments and microfinance institutions. We also pioneered a globally unique rating service for Micro, Small and Medium Enterprises (MSMEs) and significantly extended the accessibility to rating services to a wider market. Over 1,10,000 MSMEs have been rated by us.


CRISIL PRIVACY
 
CRISIL respects your privacy. We may use your contact information, such as your name, address, and email id to fulfil your request and service your account and to provide you with additional information from CRISIL.For further information on CRISIL’s privacy policy please visit www.crisil.com.


DISCLAIMER

This disclaimer forms part of and applies to each credit rating report and/or credit rating rationale that we provide (each a “Report”). For the avoidance of doubt, the term “Report” includes the information, ratings and other content forming part of the Report. The Report is intended for the jurisdiction of India only. This Report does not constitute an offer of services. Without limiting the generality of the foregoing, nothing in the Report is to be construed as CRISIL providing or intending to provide any services in jurisdictions where CRISIL does not have the necessary licenses and/or registration to carry out its business activities referred to above. Access or use of this Report does not create a client relationship between CRISIL and the user.

We are not aware that any user intends to rely on the Report or of the manner in which a user intends to use the Report. In preparing our Report we have not taken into consideration the objectives or particular needs of any particular user. It is made abundantly clear that the Report is not intended to and does not constitute an investment advice. The Report is not an offer to sell or an offer to purchase or subscribe for any investment in any securities, instruments, facilities or solicitation of any kind or otherwise enter into any deal or transaction with the entity to which the Report pertains. The Report should not be the sole or primary basis for any investment decision within the meaning of any law or regulation (including the laws and regulations applicable in the US).

Ratings from CRISIL Rating are statements of opinion as of the date they are expressed and not statements of fact or recommendations to purchase, hold, or sell any securities / instruments or to make any investment decisions. Any opinions expressed here are in good faith, are subject to change without notice, and are only current as of the stated date of their issue. CRISIL assumes no obligation to update its opinions following publication in any form or format although CRISIL may disseminate its opinions and analysis. CRISIL rating contained in the Report is not a substitute for the skill, judgment and experience of the user, its management, employees, advisors and/or clients when making investment or other business decisions. The recipients of the Report should rely on their own judgment and take their own professional advice before acting on the Report in any way.

Neither CRISIL nor its affiliates, third party providers, as well as their directors, officers, shareholders, employees or agents (collectively, “CRISIL Parties”) guarantee the accuracy, completeness or adequacy of the Report, and no CRISIL Party shall have any liability for any errors, omissions, or interruptions therein, regardless of the cause, or for the results obtained from the use of any part of the Report. EACH CRISIL PARTY DISCLAIMS ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY, SUITABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE. In no event shall any CRISIL Party be liable to any party for any direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees, or losses (including, without limitation, lost income or lost profits and opportunity costs) in connection with any use of any part of the Report even if advised of the possibility of such damages.

CRISIL Ratings may receive compensation for its ratings and certain credit-related analyses, normally from issuers or underwriters of the instruments, facilities, securities or from obligors. CRISIL’s public ratings and analysis as are required to be disclosed under the regulations of the Securities and Exchange Board of India (and other applicable regulations, if any) are made available on its web sites, www.crisil.com (free of charge). Reports with more detail and additional information may be available for subscription at a fee – more details about CRISIL ratings are available here: www.crisilratings.com.

CRISIL and its affiliates do not act as a fiduciary. While CRISIL has obtained information from sources it believes to be reliable, CRISIL does not perform an audit and undertakes no duty of due diligence or independent verification of any information it receives and / or relies in its Reports. CRISIL keeps certain activities of its business units separate from each other in order to preserve the independence and objectivity of the respective activity. As a result, certain business units of CRISIL may have information that is not available to other CRISIL business units. CRISIL has established policies and procedures to maintain the confidentiality of certain non-public information received in connection with each analytical process. CRISIL has in place a ratings code of conduct and policies for analytical firewalls and for managing conflict of interest. For details please refer to: https://www.crisil.com/en/home/our-businesses/ratings/regulatory-disclosures/highlighted-policies.html

CRISIL’s rating criteria are generally available without charge to the public on the CRISIL public web site, www.crisil.com. For latest rating information on any instrument of any company rated by CRISIL you may contact CRISIL RATING DESK at CRISILratingdesk@crisil.com, or at (0091) 1800 267 1301.

This Report should not be reproduced or redistributed to any other person or in any form without a prior written consent of CRISIL.

All rights reserved @ CRISIL